Key Takeaways
UroGen acquired an oncolytic virus, ICVB-1042, from IconOVir Bio at an attractive price – just $4m upfront in equity.
The company plans to develop ICVB-1042 to be a locally administered therapy for bladder cancer and other cancers.
UroGen’s top priority remains getting UGN-102, now under FDA review, to market, CEO Liz Barrett said.
As UroGen prepares to bring a second drug to market later this year, the company is also expanding its early pipeline for long-term expansion
UroGen plans to develop ICVB-1042 to be a locally administered therapy for bladder cancer and other cancers, fitting with the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?